Glioblastoma Therapy: Past, Present and Future

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer. Although great efforts have been made by clinicians and researchers, no significant improvement in survival has been achieved since the Stupp protocol became the standard of care (SOC) in 2005. Despite multimodality treatments, recurrence is almost universal with survival rates under 2 years after diagnosis. Here, we discuss the recent progress in our understanding of GB pathophysiology, in particular, the importance of glioma stem cells (GSCs), the tumor microenvironment conditions, and epigenetic mechanisms involved in GB growth, aggressiveness and recurrence. The discussion on therapeutic strategies first covers the SOC…

• EC
  European Commission

  Awards: 10.13039/501100011033, 13039/501100011033, 501100011033, UP2021-021, AEI/10.13039/501100011033, MCIN/AEI/ 10.13039/501100011033, MCIN/AEI/10.13039/501100011033
• UD
  Universitat de València
• AE
  Agencia Estatal de Investigación

  Awards: AEI/10.13039/501100011033, 501100011033, 10.13039/501100011033, MCIN/AEI/10.13039/501100011033, AEI/ 10.13039/501100011033, 13039, 10.13039, AEI/10, 13039/501100011033, AEI/10., MCIN/AEI/ 10.13039/501100011033